Patents Assigned to Institute Pasteur
  • Publication number: 20150050282
    Abstract: The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.
    Type: Application
    Filed: June 20, 2014
    Publication date: February 19, 2015
    Applicants: INSTITUT PASTEUR, Centre National De La Recherche Scientifique, Universite Paris Descartes
    Inventors: Laurence MULARD, Julien BOUTET, Catherine GUERREIRO, Farida NATO, Philippe SANSONETTI, Armelle PHALIPON
  • Publication number: 20150045506
    Abstract: A method for producing a polypeptide, includes at least one native ligation step using a peptide functionalized with a selenium group. The selenium peptides and compounds are also described.
    Type: Application
    Filed: March 18, 2013
    Publication date: February 12, 2015
    Applicants: UNIVERSITE LILLE 2 DROIT ET SANTE, INSTITUT PASTEUR DE LILLE
    Inventors: Oleg Melnyk, Laurent Raibaut, Nathalie Ollivier
  • Publication number: 20150018543
    Abstract: The present invention relates to 4H-pyrido[1,2-a]pyrimidin-4-one compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.
    Type: Application
    Filed: April 28, 2014
    Publication date: January 15, 2015
    Applicants: Institut Pasteur Korea, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Priscille BRODIN, Thierry CHRISTOPHE, Zaesung NO, Jaeseung KIM, Auguste GENOVESIO, Denis Philippe Cedric FENISTEIN, Heekyoung JEON, Fanny Anne EWANN, Sunhee KANG, Saeyeon LEE, Min Jung SEO, Eunjung PARK, Monica CONTRERAS DOMINGUEZ, Ji Youn NAM, Eun Hye KIM
  • Publication number: 20150011006
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Application
    Filed: July 15, 2013
    Publication date: January 8, 2015
    Applicants: Institut Pasteur, Institut National De La Sante Et De La Recherche Medicale, Centre National De La Recherche Scientifique
    Inventors: Pierre CHARNEAU, Veronique ZENNOU, Francoise PFLUMIO, Aude SIRVEN, Anne DUBART KUPPERSCHMITT
  • Patent number: 8927699
    Abstract: A thermostable mutant DNA polymerase; a method for obtaining the thernmostable mutant DNA polymerase by identifying a thermostable mutant polypeptide exhibiting enzymatic activity, wherein the thermostable mutant polypeptide is a variant of DNA polymerase I obtained from Thermus aquaticus; a polynucleotide, an expression vector, and a host cell encoding the thermostable mutant DNA polymerase; and a method of performing a reverse transcription polymerase chain reaction (RT-PCR) utilizing the thermostable mutant DNA polymerase, as well as a kit for facilitating the same.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: January 6, 2015
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Jean-Luc Jestin, Sophie Vichier-Guerre, Stephane Ferris
  • Patent number: 8927520
    Abstract: The present invention relates to compounds of formula (I): wherein Rj, R2, R3, R4, Xi, X2, X3 and Z are as defined in claim 1. The compounds are useful in the prevention and/or treatment of bacterial infections.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: January 6, 2015
    Assignees: Institut Pasteur, Institut Curie
    Inventors: Sylvie Pochet, Gilles Labesse, Muriel Gelin, Liliane Assairi, Olivier Dussurget, Guillaume Poncet-Montange
  • Publication number: 20150005367
    Abstract: The present invention relates to the field of fibrosis and inflammation and more particularly to the use of ADAM12 (A Disintegrin and Metalloproteinase 12) inhibitors to prevent or treat inflammation-induced fibrosis. The present invention also relates to the use of ADAM12 as a marker for inflammation-induced fibrosis and to the ablation of ADAM12 expressing cells as therapeutic approach to interfere with the development of pro-fibrotic cells.
    Type: Application
    Filed: September 5, 2014
    Publication date: January 1, 2015
    Applicant: Institut Pasteur
    Inventors: Lucie Peduto, Gerard Eberl
  • Patent number: 8921332
    Abstract: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: December 30, 2014
    Assignees: Children's Medical Center Corporation, Institut Pasteur
    Inventors: André Choulika, Richard C. Mulligan
  • Publication number: 20140378652
    Abstract: The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B)n(I) wherein M, T, B and n are as defined in claim 1.
    Type: Application
    Filed: March 16, 2012
    Publication date: December 25, 2014
    Applicants: Centre National de la Recherche Scientifique, Institut Pasteur
    Inventors: Sylvie Bay, Claude Leclerc, Richard Lo-Man
  • Patent number: 8906634
    Abstract: Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 9, 2014
    Assignee: Institut Pasteur
    Inventors: Marie-Lise Gougeon, Hela Saidi, Marie-Therese Melki, Beatrice Poirier-Beaudoin, Valerie Seffer
  • Publication number: 20140349946
    Abstract: The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject
    Type: Application
    Filed: May 19, 2014
    Publication date: November 27, 2014
    Applicant: INSTITUT PASTEUR
    Inventors: Catherine ROUGEOT, Jean-Francois HUAULME, Marie-Noelle UNGEHEUER, Anne WISNER, Evelyne DUFOUR
  • Patent number: 8895251
    Abstract: The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: November 25, 2014
    Assignee: Institut Pasteur
    Inventors: Catherine Rougeot, Jean-Francois Huaulme, Marie-Noelle Ungeheuer, Anne Wisner, Evelyne Dufour
  • Patent number: 8895725
    Abstract: Use of 9,10-anthraquinone compounds of formula (I) or pharmaceutical salts thereof or plant extracts containing said compounds in the preparation of anti-HCV medicaments is disclosed, in which Y1 are Y2 are independently hydrogen, hydroxyl or groups of formula (II); and R1, R2, R3, R4, R5 and R6 are independently hydrogen, hydroxyl, carboxyl, cyano group, nitro group, groups of formula (III) or groups selected from those substituted or unsubstituted groups: amino, C1-C6 aliphatic hydrocarbon, C3-C7 cyclic aliphatic hydrocarbon, C1-C6 alkoxy, C2-C7 carbalkoxy, C1-C4 acyloxy, C6-C20 aryl, or 5 to 7 members heterocyclic or benzoheterocyclic thereof; or R5 and R6 form the group of formula (IV). The compounds of present invention are cheap, safe and effective because that they mostly come from traditional Chinese medicines and have better anti-HCV effects and lighter side effects.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: November 25, 2014
    Assignees: Shanghai Institute of Pharmaceutical Industry, Institute Pasteur of Shanghai, Chinese Academy of Sciences
    Inventors: Shuguang Wang, Jin Zhong, Deyun Kong, Jue Hu, Bo Li, Wen Gao, Chunyan Gai, Changlong Zhuang, Haitao Mao
  • Patent number: 8889827
    Abstract: The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: November 18, 2014
    Assignee: Institut Pasteur
    Inventor: Catherine Rougeot
  • Publication number: 20140336119
    Abstract: The invention relates to polypeptides, defined through a consensus sequence, having a length from 10 to 80 amino-acid residues, and whose polypeptidic sequence comprises or consists of the consensus sequence P1(Xa)P3(Xb)P5(Xc)P6(Xd)P7 (SEQ ID NO: 1), presenting specific patterns. The polypeptides of the invention target glycosylated Muc2 proteins. The invention also relates to methods of synthesis of such polypeptides, to their nucleic acids and uses thereof. The polypeptidic sequence of the polypeptides of the invention can be part of the N-terminal sequence of a mucus-binding (MUB) domain, especially a mucus-binding (MUB) domain of several species. The invention also relates to chimeric molecule(s) comprising such polypeptides, which are labelled, and vectors, especially plasmids and population of cells or composition comprising polypeptides of the invention. Synthesis methods encompass biotechnological or chemical production.
    Type: Application
    Filed: September 7, 2012
    Publication date: November 13, 2014
    Applicant: INSTITUT PASTEUR
    Inventors: Benoit Marteyn, Yves-Marie Coic, Francoise Baleux, Philippe Sansonetti
  • Patent number: 8883173
    Abstract: The current invention relates to the diagnosis and treatment of diseases resulting from infections by Mycobacterium avium subsp. paratuberculosis. In particular the invention relates to the use of an antigen selected among (a) a synthetic peptide 5P having the following formula: DPhe-NMeVal-Ile-Phe-Ala-OMe (SEQ ID NO: 1); (b) a lipopeptide L5P consisting of the synthetic peptide a) wherein the N-terminal phenylalanine residue is N-acylated with an eicosanoic acid acyl chain; (c) a variant of peptide a) or lipopeptide b) able to react with anti-Mycobacterium paratuberculosis antibodies; for in vitro detection or quantification of specific anti-Mycobacterium paratuberculosis antibodies in a biological sample.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: November 11, 2014
    Assignees: Institut National de la Sante et de la Recherche Medicale (Inserm), Institut National de la Recherche Agronomique, Institut Pasteur
    Inventors: Sylvie Bay, Franck Biet
  • Patent number: 8865734
    Abstract: The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: October 21, 2014
    Assignees: Institut Pasteur Korea, Institut National de la Sante et de la Rech
    Inventors: Zaesung No, Jaeseung Kim, Priscille Brodin, Min Jung Seo, Young Mi Kim, Jonathan Cechetto, Heekyoung Jeon, Auguste Genovesio, Saeyeon Lee, Sunhee Kang, Fanny Anne Ewann, Ji Youn Nam, Thierry Christophe, Denis Philippe Cedric Fenistein, Jamung Heo, Jang Jiyeon
  • Publication number: 20140309238
    Abstract: The present invention relates to compounds of Formula (I), wherein R1 is chosen among the following radicals: (II); (III); (IV), (V), (VI) (VII) and n=1 or 2 and m=1 or 2 with the proviso that m=2 when R1 is (VIII). The present invention also relates to the use thereof as drugs, more particularly in the treatment of mycobacterial infections and more particularly in the treatment of tuberculosis.
    Type: Application
    Filed: October 24, 2012
    Publication date: October 16, 2014
    Applicants: Universite de Droit et de la Sante de Lille 2, INSERM (Institut National de la Sante et de la Recherche Medicale), Institut Pasteur de Lille
    Inventors: Benoit Deprez, Nicolas Willand, Marion Flipo, Matthieu Desroses, Alain Baulard, Florence Leroux
  • Publication number: 20140308755
    Abstract: The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid sample obtained from a patient, and the use of this method in the prognostic and/or diagnosis of neurological disorders. These methods are in particular applicable to the monitoring of the human immunodeficiency virus (HIV) infection of a subject who is known to be infected with HIV and in the prognostic and/or diagnostic of the state of progression of Acquired immune deficiency syndrome (AIDS) or the state of progression toward AIDS, in particular the state of progression or the state of progression toward neurological disorders associated with AIDS. Finally, the invention is also about method to determine the immune deficiency or level of immune activation of a patient, in particular a HIV-infected patient.
    Type: Application
    Filed: May 6, 2014
    Publication date: October 16, 2014
    Applicant: INSTITUT PASTEUR
    Inventors: Marie-Lise Gougeon, Beatrice Poirier-Beaudoin, Valerie Seffer, Hela Saidi
  • Patent number: 8859240
    Abstract: The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre-m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: October 14, 2014
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Frédéric Tangy, Philippe Despres, Chantal Combredet, Marie Pascale Frenkiel